ASSEMBLY BIOSCIENCES INC
NASDAQ: ASMB (Assembly Biosciences, Inc.)
Kemas kini terakhir: 2 jam lalu36.60
0.47 (1.30%)
| Penutupan Terdahulu | 36.13 |
| Jumlah Dagangan | 156,451 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.69 |
| Harga / Jualan (P/S) | 7.90 |
| Harga / Buku (P/B) | 2.41 |
| Julat 52 Minggu |
| Margin Keuntungan | -124.15% |
| Margin Operasi (TTM) | -105.54% |
| EPS Cair (TTM) | -6.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.13% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | -56.19 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.50 M |
| Pulangan Atas Aset (ROA TTM) | -25.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -133.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Assembly Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.17 |
|
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 39.25% |
| % Dimiliki oleh Institusi | 12.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Seven Fleet Capital Management Lp | 30 Jun 2026 | 433,147 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |